Hypofractionated lung adenocarcinoma stage 3a, or stage IIIa. The five-year survival rate of patients is about 15% after active treatment.
Lung adenocarcinoma is a common malignant tumor of the respiratory system, which can be caused by multiple factors such as smoking, heredity and environment. Hypofractionation means that the cancer cells are of low differentiation grade, which suggests a poor prognosis.
Stage IIIa is one of its clinical stages, which can be expressed as T1a~2bN2M0, T3N1M0 and so on.
In this period, patients can be treated with preoperative neoadjuvant chemotherapy, surgery, postoperative adjuvant therapy, etc. The five-year survival rate is about 15% after active treatment.
Patients should build up confidence to fight against the disease, consult the doctor in a timely manner, complete relevant examinations, make a clear diagnosis, and then take appropriate treatment programs.